✓ Translated by DotMD AI Clinical Council Source: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation • Phase III Randomized Trial

Verify Primary Source: NIH PubMed PMID #39613120 ↗

Phase III Randomized Trial: Maribavir for refractory cytomegalovirus infection (with or without resistance) in solid organ transplant recipients: Subgroup analysis of the phase 3 randomized SOLSTICE study (N = 211)

Original Paper Title: “Maribavir for refractory cytomegalovirus infection (with or without resistance) in solid organ transplant recipients: Subgroup analysis of the phase 3 randomized SOLSTICE study”

Elena Rostova (AI Quant) Rigor Score

82 / 100

Sample Size (Participants)

N = 211

Evidence Classification

Phase III Randomized Trial

Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways

Consistent with findings in the overall SOLSTICE population, this subgroup analysis of SOT recipients demonstrated greater effectiveness of maribavir for cytomegalovirus viremia clearance and fewer discontinuations due to treatment-emergent adverse events than IAT.
Study Design & Sample: Phase III Randomized Trial published in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (N = 211 human participants).
Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2025), this phase iii randomized trial evaluating 211 human participants investigated: In the phase 3 SOLSTICE study (NCT02931539), maribavir was superior to investigator-assigned therapy (IAT) for confirmed cytomegalovirus viremia clearance at study week 8 in hematopoietic cell/solid organ transplant (HCT/SOT) recipients. Key clinical takeaway: Consistent with findings in the overall SOLSTICE population, this subgroup analysis of SOT recipients demonstrated greater effectiveness of maribavir for cytomegalovirus viremia...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2025-06-15; N = 211; Rigor 82/100): Consistent with findings in the overall SOLSTICE population, this subgroup analysis of SOT recipients demonstrated greater effectiveness of maribavir for cytomegalovirus viremia clearance and fewer discontinuations due to treatment-emergent adverse events than IAT.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: solstice-pain-relieving-camphor-menthol-methyl-salicylate → Condition: hemorrhagic-fevers → Condition: histoplasmosis →

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 39613120: Phase III Randomized Trial: Maribavir for refractory cytomegalovirus infection (with or without resistance) in solid organ transplant recipients: Subgroup analysis of the phase 3 randomized SOLSTICE study (N = 211)

3 of 3 Free Questions Remaining